GT Biopharma, Inc. carries no debt; cash flow comfortably covers obligations.

GT Biopharma, Inc.'s free cash flow has decreased 0.08% from $-12.90M last year to $-12.91M, signaling decreasing performance

GT Biopharma, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

GT Biopharma, Inc. has insufficient data to evaluate this check.

GT Biopharma, Inc. has a net cash position, so leverage is healthy.

GT Biopharma, Inc. carries no debt; interest obligations are fully covered.

GT Biopharma, Inc. has insufficient data to evaluate this check.

GT Biopharma, Inc.'s short-term assets of $8.11M exceed its short-term liabilities of $2.32M

GT Biopharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

GT Biopharma, Inc.'s return on equity of -901.32%, is lower than 15.00%, indicating bad performance

GT Biopharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

GT Biopharma, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

GT Biopharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

GT Biopharma, Inc. has negative free cash flow, indicating cash burn

GT Biopharma, Inc.'s yearly earnings has decreased 115.42% since last year from $-13.16M to $-28.35M, signaling decreasing performance

GT Biopharma, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -204.98% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

GT Biopharma, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

GT Biopharma, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

GT Biopharma, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

GT Biopharma, Inc. has insufficient data to evaluate this check.

GT Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GT Biopharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

GT Biopharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

GT Biopharma, Inc. has insufficient data to evaluate this check.

GT Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

GT Biopharma, Inc. has a price-to-book ratio of 1.28x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

GT Biopharma, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue